Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
10.87 ^USD	+2.94%		-1.00%	-22.25%

01/07	Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Defensive Index	CI
01/07	Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Value-Defensive Index	CI

Dynavax Technologies Corporation Appoints Kelly Macdonald as Its Senior Vice President and Principal Financial Officer, Effective March 1, 2021

January 21, 2021 at 07:31 pm IST

Dynavax Technologies Corporation announced that on January 19, 2021, Dynavax Technologies Corporation appointed Kelly MacDonald as its Senior Vice President and Principal Financial Officer, effective upon her start date, which is expected to be March 1, 2021.

Latest news about Dynavax Technologies Corporation

Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Defensive Index	01/07	CI
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Value-Defensive Index	01/07	CI
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Growth-Defensive Index	01/07	CI
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial	28/06	MT
Dynavax Technologies Corporation Initiates Phase 1/2 Study of Novel Shingles Vaccine Program	28/06	CI
Transcript : Dynavax Technologies Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 04:00 PM	11/06
Dynavax Technologies Corporation Reappoints Ernst & Young LLP as Independent Registered Public Accounting Firm	25/05	CI
Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data	14/05	MT
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA	14/05	DJ
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine	14/05	RE
Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S	14/05	CI
Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024	09/05
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M	09/05	MT
Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024	09/05	CI
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Dynavax Technologies Corporation Announces Chief Financial Officer Changes	02/04	CI
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	23/02	MT
Transcript : Dynavax Technologies Corporation, Q4 2023 Earnings Call, Feb 22, 2024	23/02
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M	23/02	MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024	23/02	CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02	CI
Goldman Sachs Initiates Dynavax Technologies at Neutral Rating With $20 Price Target	01/02	MT
Transcript : Dynavax Technologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	12/01
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to NASDAQ Biotechnology Index	18/12	CI

Chart Dynavax Technologies Corporation

Duration

Period

More charts

Company Profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Dynavax Technologies Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.56 USD

Average target price

25.91 USD

Spread / Average Target

+145.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DYNAVAX TECHNOLOGIES CORPORATION	-22.25%	138.22Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr
ARGENX SE	+25.44%	2.77TCr
BIONTECH SE	-17.74%	2.03TCr
GENMAB A/S	-15.17%	1.68TCr
BEIGENE, LTD.	-15.21%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+54.50%	1.44TCr

Bio Therapeutic Drugs